Pharsight

Truseltiq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9067896 HELSINN HLTHCARE Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof
Aug, 2028

(4 years from now)

US8552002 HELSINN HLTHCARE Compounds and compositions as protein kinase inhibitors
Aug, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160804 HELSINN HLTHCARE Pharmaceutical dosage forms
Dec, 2034

(10 years from now)

US10278969 HELSINN HLTHCARE Pharmaceutical dosage forms
Dec, 2034

(10 years from now)

Truseltiq is owned by Helsinn Hlthcare.

Truseltiq contains Infigratinib Phosphate.

Truseltiq has a total of 4 drug patents out of which 0 drug patents have expired.

Truseltiq was authorised for market use on 28 May, 2021.

Truseltiq is available in capsule;oral dosage forms.

Drug patent challenges can be filed against Truseltiq from 28 May, 2025.

The generics of Truseltiq are possible to be released after 11 December, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2026
Orphan Drug Exclusivity(ODE-353) May 28, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

TRUSELTIQ family patents

Family Patents